Acquisition by Boylan James P of 40000 shares of Compass Therapeutics at 1.96 subject to Rule 16b-3
| CMPX Stock | USD 1.63 0.07 4.49% |
Slightly above 68 percent of all Compass Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Compass Therapeutics suggests that a large number of traders are confidant. Compass Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Compass Therapeutics' earnings reports, geopolitical events, and overall market trends.
Compass |
Filed transaction by Compass Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Cash Flow Correlation
Compass Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Compass Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Compass Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Compass Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Compass Therapeutics Fundamental Analysis
We analyze Compass Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Compass Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Compass Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Compass Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Compass Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Compass Therapeutics stock to make a market-neutral strategy. Peer analysis of Compass Therapeutics could also be used in its relative valuation, which is a method of valuing Compass Therapeutics by comparing valuation metrics with similar companies.
Peers
Compass Therapeutics Related Equities
| CUE | Cue Biopharma | 11.93 | ||||
| MOLN | Molecular Partners | 0.17 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| INBX | Inhibrx | 2.37 |
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.